🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to health experts.

An International Challenge

The sexually transmitted infection are on the rise worldwide, with data suggesting over 82 million infections annually. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the context of rising global incidence, the spread of superbugs and the highly restricted treatment choices presently on offer.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has classified it as a "critical concern". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Authorization

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists hope that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The charitable organization GARDP partnered with the drug firm its industry partner to see it through.

“This authorization marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Testing Data and Worldwide Availability

According to findings released by a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which combines a dual-drug approach. The trial included hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the ability to license and sell the drug in numerous low-income and middle-income countries.

Doctors directly involved have expressed positive views. The availability of a single-dose, oral treatment of this kind is seen as a "revolutionary step" for public health efforts. This is considered essential to alleviate the strain of the infection for people and to prevent the spread of extremely resistant gonorrhoea globally.